References
- Gharib H, James E M, Charboneau J W, Naessens J M, Offord K P, Gorman C A. Suppressive therapy with levothyroxine for solitary thyroid nodules. N Engl J Med 1993; 317: 70–5
- Papini E, Bacci V, Panunzi C, Pacella C M, Fabbrini R, Bizarri G, et al. A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol 1993; 38: 507–13
- Thomas C G, Jr. Hormonal treatment of thyroid cancer. J Clin Endocrinol Metab 1993; 17: 232–7
- Clark O H. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1993; 5: 39–47
- Cady B, Cohn K, Rossi R L, Sedgwick C E, Meissner W A, Werber J, et al. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 1993; 94: 978–83
- Thomas C G, Jr. Role of thyroid stimulating hormone suppression in the management of thyroid cancer. Semin Surg Oncol 1993; 7: 115–9
- Mazzaferri E L. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553–9
- Ross D S, Neer R M, Ridgway E C, Daniels G H. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1993; 82: 1167–70
- Paul T L, Kerrigan J, Kelly A M, Braverman L E, Baran D T. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. J Am Med Assoc 1993; 259: 3137–41
- Featherstone L H, Stewart D K. Angina in thyrotoxicosis. Arch Intern Med 1993; 143: 554–5
- Ikram H. The nature and prognosis of thyrotoxic heart disease. Quart J Med 1993; 54: 19–28
- Wayne E J. Clinical and metabolic studies in thyroid disease. Br Med J 1960; i: 1–11; 78–90
- Weissler A M, Harris W S, Schoenfeld C D. Bedside techniques for the evaluation of ventricular function in man. Am J Cardiol 1993; 23: 577–83
- Taimela E, Koskinen P, Irjala K. Time-resolved immunofluorometric assay for thyrotropin improved for enhanced functional sensitivity and clinical discrimination. Scand J Clin Lab Invest 1993; 54: 317–21
- Beck J R, Shultz E K. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1993; 110: 13–20
- Hanley J A, McNeil B J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1993; 143: 29–36
- Larsen P R, Silva J E, Kaplan M M. Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocrine Rev 1993; 2: 87–102
- Jennings P E, O'Malley B P, Griffin K E, Northover B, Rosenthal F D. Relevance of increased serum thyroxine concentrations associated with normal serum triiodothyronine values in hypothyroid patients receiving thyroxine: a case for “tissue thyrotoxicosis”. Br Med J 1993; 289: 1645–7
- Gow S M, Caldwell G, Toft A D, Seth J, Hussey A J, Sweeting V M, et al. Relationship between pituitary and other target organ responsiveness in hypothyroid patients receiving thyroxine replacement. J Clin Endocrinol Metab 1993; 64: 364–70
- Nuutila P, Irjala K, Saraste M, Seppälä P, Viikari J. Cardiac systolic time intervals and thyroid hormone levels during treatment of hypothyroidism. Scand J Clin Lab Invest 1993; 52: 467–77
- Grund F M, Niewoehner C B. Hyperthyroxinemia in patients receiving thyroid replacement therapy. Arch Intern Med 1993; 149: 921–4
- Nicoloff J T, Spencer C A. The use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab 1993; 71: 553–8
- Fraser W D, Biggart E M, O'Reilly D StJ, Gray H W, McKillop J H, Thomson J A. Are biochemical tests of thyroid function of any value in monitoring patients receiving thyroxine replacement? Br Med J 1986; 293: 808–10
- Fyffe J A, Ayoub L, Cohen H N, Turner J G, Thomson J A, Ratcliffe J G. Clinical and laboratory evaluation of four methods of assessing free thyroxine status in thyroid clinic patients. Ann Clin Biochem 1993; 17: 334–8
- Herman V S, Joffe B I, Kalk W J, Panz V, Wing J, Seftel H C. Clinical and biochemical responses to nadolol and clonidine in hyperthyroidism. J Clin Pharmacol 1993; 29: 1117–20
- Salmi J, Lamberg B-A, Ebeling P. Absence of TRH-response to TRH and measurement of systolic time intervals for the assessment of the optimal thyroxine doses in the treatment of patients with differentiated thyroid carcinoma. Advances in thyroid neoplasia, M Andreoli, F Monaco, J Robbins. Field Education, RomeItaly 1981; 317–23
- Boudoulas H. Systolic time intervals. Eur Heart J 1993; 11: 93–104
- Nyström E, Lundberg P-A, Petersen K, Bengtsson C, Lindstedt G. Evidence for a slow tissue adaptation to circulating thyroxine in patients with chronic 1-thyroxine treatment. Clin Endocrinol 1993; 31: 143–50